

PD Dr. Thomas Longerich
Institute of Pathology, Heidelberg

Institute of Pathology
Im Neuenheimer Feld 224
69120 Heidelberg
06221 56 4173 (phone)
06221 56 5251 (fax)
thomas.longerich@med.uni-heidelberg.de

SCIENTIFIC VITA:

1995-2002	Study of Medicine, University of Cologne
2003	Internship, Institute of Pathology, University of Cologne
2003	MD-Thesis (magna cum laude, Institute of Pathology, University of Cologne)
1/04 – 6/04	Internship, Department of General Surgery, University of Heidelberg
Since then	Department of General Pathology and Pathological Anatomy, University of Heidelberg
Since 2007	Research group leader, Institute of Pathology, University of Heidelberg
2009	Board Certification in Pathology
2010	Consultant pathologist for Hepatopathology
2011	Postdoctoral Lecture Qualification (Habilitation)
Since 2012	Senior pathologist

AWARDS:

2011	Poster award, 27 th Annual Meeting of the German Association for the Study of Liver disease (GASL), Regensburg
2012	Nobel Peace Prize (as resident of the European Union)

FIELDS OF INTEREST

Morphological and molecular pathology of liver disease in humans and mice.
Array-based screening in hepatocellular carcinoma.
Molecular classification of human hepatocellular carcinoma.
Functional inactivation of TP53 in hepatocellular carcinoma.

SELECTED PUBLICATIONS

Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Bermejo JL, Longerich T (2012) Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. **Hepatology** 56:1817-1827

Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H (2012) Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and

increases hepatocarcinogenesis in mice. **J Hepatol.** 2012 Jun 21. [Epub ahead of print]

Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C (2012) Nuclear Pore Component Nup98 Is a Potential Tumor Suppressor and Regulates Posttranscriptional Expression of Select p53 Target Genes. **Mol Cell.** 2012 Oct 24. doi:pii: S1097-2765(12)00820-9. 10.1016/j.molcel.2012.09.020. [Epub ahead of print]

Longerich T, Müller MM, Breuhahn K, Schirmacher P, Benner A, Heiss C (2012) Oncogenetic tree modeling of human hepatocarcinogenesis. **Int J Cancer** 130:575-583.

Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. **Nature** 479:547-551.

Maass T, Thieringer FR, Mann A, Longerich T, Schirmacher P, Strand D, Hansen T, Galle PR, Teufel A, Kanzler S (2011) Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. **Int J Cancer** 128:1259-1268.

Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R (2011) Recruitment and Activation of a Lipid Kinase by Hepatitis C Virus NS5A Is Essential for Integrity of the Membranous Replication Compartment. **Cell Host Microbe** 9:32-45.

Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K (2011) Annexin A2 as a differential diagnostic marker of hepatocellular tumours. **Pathol Res Pract** 207:8-14.

Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, Breinig M, Warth A, Vogel MN, Mittelbronn M, Mehrabi A, Gdynia G, Penzel R, Longerich T, Breuhahn K, Popanda O, Plass C, Schirmacher P, Kern MA (2010) Down-regulation of tumor suppressor a kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. **Hepatology** 52:2023-2033

Stange DE, Engel F, Longerich T, Koo BK, Koch M, Delhomme N, Aigner M, Toedt G, Schirmacher P, Lichter P, Weitz J, Radlwimmer B (2010) Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. **Gut** 59:1236-1244.

Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia V, Evert M, Dombrowski F, Schirmacher P, Longerich T (2010) Oncogenic and tumor suppressive roles of Polo-like kinases in human hepatocellular carcinoma. **Hepatology** 51:857-868

Németh J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J (2009) S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. **Hepatology** 50:1251-1262.

Schirmacher P, Longerich T (2009) Hochdifferenzierte Lebertumoren - Neue Entwicklungen und ihre diagnostische Relevanz. **Pathologe** Suppl 2:200-206.

Longerich T, Schirmacher P (2009) Neue Entwicklungen in der Biopsiediagnostik früher und unklarer Lebertumoren. **Z Gastroenterol** 47:30-36.

Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, Schirmacher P, Breuhahn K (2009) Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. **Hepatology** 50:1130-1139.

Esposito I, Born D, Bergmann F, Longerich T, Welsch T, Giese NA, Büchler MW, Kleeff J, Friess H, Schirmacher P (2008) Autoimmune pancreatocholangitis, non-autoimmune pancreatitis and primary sclerosing cholangitis: a comparative morphological and immunological analysis. **PLoS One** 3:e2539.

Schlaeger C*, Longerich T*, Schiller C, Bewerunge P, Mehrabi A, Toedt G, Kleeff J, Ehemann V, Eils R, Lichter P, Schirmacher P, Radlwimmer B (2008) Etiology-dependent and -independent molecular mechanisms in human hepatocarcinogenesis defined by MYC, MDM4 and EEF1A2. **Hepatology** 47:511-520. (**shared first authorship*)

Longerich T, Flechtenmacher C, Schirmacher P (2008) Maß und Zahl in der Hepatopathologie. **Pathologe** 29:15-26.

Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P, Sinn HP (2008): Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. **Breast Cancer Res Treat** 107:331-335.

Loddenkemper C*, Longerich T*, Hummel M, Ernestus K, Anagnostopoulos I, Dienes HP, Schirmacher P, Stein H (2007): Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. **Virchows Arch** 450:493-502. (**shared first authorship*)

Aulmann S, Longerich T, Schirmacher P, Mechttersheimer G, Penzel R (2007): Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. **Histopathology** 50:881-886.

Wurstthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J (2006) Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. **Hepatology** 44:675-684.

Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. **Oncogene** 25:3787-3800